Topline: Oral Semaglutide Cuts Cardiovascular Events in T2D
Oral semaglutide (Rybelsus) lowered the risk for major adverse cardiovascular events (MACEs) by a significant 14% compared with placebo, Novo...
Oral semaglutide (Rybelsus) lowered the risk for major adverse cardiovascular events (MACEs) by a significant 14% compared with placebo, Novo...